

Mast Cell Biology at Molecular Level: a Comprehensive Review

Daniel Elieh Ali Komi^{1,2} · Stefan Wöhrl³ · Leonard Bielory^{4,5,6}

Published online: 12 December 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

Mast cells (MCs) are portions of the innate and adaptive immune system derived from bone marrow (BM) progenitors that are rich in cytoplasmic granules. MC maturation, phenotype, and function are determined by their microenvironment. MCs accumulate at inflammatory sites associated with atopy, wound healing, and malignancies. They interact with the external environment and are predominantly located in close proximity of blood vessels and sensory nerves. MCs are key initiators and modulators of allergic, anaphylactic, and other inflammatory reactions, by induction of vasodilation, promoting of vascular permeability, recruitment of inflammatory cells, facilitation of adaptive immune responses, and modulation of angiogenesis, and fibrosis. They express a wide range of receptors, e.g., for IgE (FcεRI), IgG (FcγR), stem cell factor (SCF) (KIT receptor or CD117), complement (including C5aR), and cytokines, that upon activation trigger various signaling pathways. The final consequence of such ligand receptor–based activation of MCs is the release of a broad array of mediators which are classified in three categories. While some mediators are preformed and remain stored in granules such as heparin, histamine, and enzymes mainly chymase and tryptase, others are de novo synthesized only after activation including LTB₄, LTD₄, PDG₂, and PAF, and the cytokines IL-10, IL-8, IL-5, IL-3, IL-1, GM-CSF, TGF-β, VEGF, and TNF-α. Depending on the stimulus, MCs calibrate their pattern of mediator release, modulate the amplification of allergic inflammation, and are involved in the resolution of the immune responses. Here, we review recent findings and reports that help to understand the MC biology, pathology, and physiology of diseases with MC involvement.

Keywords FcεRI · IgE · KIT receptor · Mast cell · Mediators · Stem cell factor

Abbreviations

BM	Bone marrow
CM	Cutaneous mastocytosis
DAMPs	Damage-associated molecular patterns
HCMCs	Human cultured mast cells
JAK	Janus kinase

LAT	Linker for activator of T cells
LT	Leukotriene
MC	Mast cell
MCp	Mast cell progenitor
NGF	Nerve growth factor
PAMPs	Pathogen-associated molecular patterns
PAR2	Protease-activated receptor2
PG	Prostaglandin
RER	Rough endoplasmic reticulum
SCF	Stem cell factor
SG	Secretory granules
SM	Systemic mastocytosis
SM-AHNMD	SM with associated clonal hematological non–mast cell lineage disease
Syk	Spleen tyrosine kinase
VEGF	Vascular endothelial growth factor

✉ Leonard Bielory
 drlbielory@gmail.com

¹ Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

² Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran

³ Floridsdorf Allergy Center (FAZ), Vienna, Austria

⁴ Department of Medicine and Ophthalmology, Hackensack Meridian School of Medicine at Seton Hall University, 400 Mountain Avenue, Springfield, NJ 07081-2515, USA

⁵ Department of Medicine, Thomas Jefferson University Sidney Kimmel School of Medicine, Philadelphia, PA, USA

⁶ Rutgers University Center of Environmental Prediction, New Brunswick, NJ, USA

Introduction

Paul Ehrlich was the first who used the term “Mastzellen” when he observed the granular cells in slides obtained from

connective tissues and stained with aniline dyes. The German word “Mast” (from the original Greek word $\mu\alpha\sigma\tau\acute{o}\sigma$ = breast) mirrors the nourishing and “suckling” functions of MCs [1]. Using commercial dyes such as dahlia, toluidine blue (the stain of choice widely recommended for MC identification staining MC heparin), methylene blue (thiazine dye staining the anionic residues packed in the MC granules), and neutral red (azine dye), Ehrlich noted metachromatically staining of mature MCs in the connective tissue of several organs [2–5]. Since their discovery, an extensive understanding of MC biology has been published, which is highlighted in (Fig. 1) [3, 6–26]. MCs are terminally differentiated, highly distributed through the body, and granular immune cells of BM hematopoietic origin which derive from CD34+/CD117+ progenitor cells. MC progenitors then systemically migrate to target tissues, primarily those with direct contact to environmental antigens including the skin and the mucosal surfaces of the eye, respiratory, and gastrointestinal tracts. MCs complete the final biologic stages of differentiation and maturation in target tissues in the presence of the local growth factors including IL-9, IL-10, IL-3, IL-4, IL-33, CXCL12, nerve growth factor

(NGF), and TGF- β [27]. The process of MC development from their progenitors is strictly controlled by microenvironmental stimuli that lead to considerable subtype differences [28]. In humans, MCs are traditionally classified based on the chemical composition of produced serine proteases, tryptase and chymase. MCs containing only tryptase (MC_T) predominantly reside in the alveolar septa and the mucosa of the small intestine; MCs containing chymase (MC_C) commonly reside in synovial tissue; and MC containing tryptase and chymase (MC_{TC}) are generally found in the skin, submucosal layers of the small intestine, and tonsils. MCs of rodents are classified a slightly different according to their phenotypic properties in two main subsets that have been identified as connective tissue MCs (CTMCs) located in the skin and peritoneal cavity and the mucosal MCs (MMC) residing in the Lamina propria layer of the intestine [28]. Murine MCs unlike those in human are IL-3 dependent, but SCF independent for growth and expansion [29]. In vivo BM-derived MCs (BMMCs) resemble gastrointestinal mucosa residing MCs (MMCs) when cocultured with IL-3, whereas connective tissue MCs (CTMCs) isolated from the peritoneal cavity are IL-3




Fig. 1 Timeline highlighting the advances in mast cell biology. From the initial sighting of the MCs in 1863, there has been advances on the physical characteristics of identification staining techniques based on

content while more functional changes have demonstrated the evolution of various subtypes with similar physical characteristics

and IL-4 dependent. Various immunologically activated resident cells including fibroblasts, T cells, and MCs produce IL-3 and IL-4 providing hematopoietic growth factors for other cell types [30]. Each MC contains approximately 1000 granules in the cytoplasm. The morphology of MCs appears to depend on the anatomical location with sizes ranging from 5 to 20 μm , varying from rounded-shaped to elongated forms, which are typical for perivascular MCs [31]. MCs can be activated via several pathways including aggregation of IgE bound to the Fc ϵ RI by polyvalent allergen, other ligand receptor interactions, including C3a-C3aR, C5a-C5aR (CD88), IgG-Fc γ RI, and NGF-TRKA, and opioid receptors [32].m

Mast Cell Subtypes

MC subtypes have been identified based on function, histochemical staining features, enzymatic content mainly proteases, and pattern of mediator release in response to selected secretagogues [28]. In rodents, MCs are classified as either CTMCs, which can be isolated from the skin, peritoneal cavity, and intestinal submucosa, or MMCs which are predominant in the mucosal layers [33]. CTMCs express a variety of proteases that include mMCP-4, mMCP-5, mMCP-6, mMCP-7, and CPA3, whereas MMCs express mMCP-1 and mMCP-2 [33]. MMCs can also be differentiated by their T cell-mediated expansion in response to certain parasites [28] (Table 1). The main subclasses of MCs in human classified according to protease content include “MC_T” that express tryptase only and the “MC_{TC}” that are known for their

capability of expressing both tryptase and chymase [40] as well as MC-CPA [41] (Table 2).

Human MCs express γ -tryptase (also known as hTMT) which is a transmembrane tryptase exposed at the cell surface after the cell degranulates the cytoplasmic granules [41]. MC heterogeneity mirrors the experience that they gain in each specific tissue. In addition to the classical tryptases and chymases, resident MCs of various organs express peculiar factors, and release mediators responsible for their tissue-specific functions. For instance, skin MCs have low TLR expression but release carboxypeptidase, while intestinal MCs express $\alpha 2\beta 7$, $\alpha 2\beta 1$, and P2X7, have high TLR expression (in small intestine), and release cysteinyl leukotrienes [46]. Based on the fact that MC heterogeneity is the result of differences in tissue specificity, gene expression programs controlled by microenvironmental factors and stimuli that provoke their activation and/or degranulation, it is suggested to revise the historical classification of these cells according to their protease content [46] toward a classification that better reflects their functional state.

Phylogeny and Lineage Development

The egress of hematopoietic cells into the circulation in an identifiable mature state had secluded the origin of MCs as a mystery for decades. However, owing to advancement in the multicolor flow cytometry technique, and the availability of MC-specific antibodies such as mAb AA4 and mAb BGD6, characterization of the MC progenitors in terms of surface

Table 1 Comparing various characteristics of rodent MC subsets

Characteristic	(Connective tissue-type MCs) CTMCs	(Mucosal-type MCs) MMC	Ref
Size	Larger (10–20 μm)	Smaller (5–10 μm)	[34]
Formaldehyde fixation	Resistant	Sensitive	[35]
Staining	Safranin	Alcian Blue	[36]
Granule neutral protease	Chymase (RMCP I), tryptase, proteinase 5, carboxypeptidase A	Chymase (RMCP II)	[35]
Granule proteoglycan content	Heparin proteoglycan	Chondroitin sulfate E proteoglycan	[36]
T cell dependence	T cell independent	T cell-dependent in vivo	[35]
Heparin content	High	Low	[34]
Histamine content	High	Low	[36]
Fixators used in staining	Most of fixators including formalin	Only Carnoy's fixator or a mixture of formaldehyde and acetic acid	[34]
Cytokine needed to proliferation	IL-3 independent, IL-3 and IL-4 only synergistically support their proliferation	IL-3-dependent in vitro	[36, 37]
Compound 48/80-mediated activation	Yes	No	[38]
Polymyxin-mediated activation	Yes	No	[38]
Activated by substance P	Yes	No	[39]
Distribution in gastrointestinal tract	Widely distributed in submucosa, serosa, and mesentery	Restricted to the lamina propria	[34]

Table 2 Comparing various characteristics of human MC subsets

Characteristic	MC _T	MC _{TC}	Ref
Distribution	Predominant subtype in small intestinal mucosa (98%) and alveoli (93%)	Predominant subtype in the skin (88%) and small intestinal submucosa (87%)	[42]
Granule neutral protease	Tryptase	Tryptase, chymase, carboxypeptidase, cathepsin G	[43]
Granule ultrastructure	Cylindrical scrolls	Crystals (lattices/gratings)	[44]
T cell dependence	Yes	No	[35]
Sensitive to compound 48/80	No	Yes	[35]
Analogous to rodent MCs	MMC	CTMC	[45]
Sensitive to substance P	No	Yes	[35]
Inhibited by sodium cromoglycate	Yes	No	[35]

markers development and homing became possible [47–49]. Kitamura and coworkers provided the first evidence that MCs derive from progenitors of BM origin, using the beige mouse model (C57BL-B6j/B6j). Three-month-old wild-type mice were irradiated and adoptively transferred with BM cells of either beige or wild-type mice. Tissue samples obtained from the caecum and dorsal skin of recipient mice showed that most of the MCs in the caecum were of donor origin, whereas the majority of skin residing MCs were of host origin, indicating that the adoptively transferred BM cells differentiate finally to tissue MCs [50]. Gurish and coworkers demonstrated that MCPs in mice are of BM origin by eliminating them with sublethal doses of γ -radiation and reconstitution with syngeneic BM. Since $\beta 7$ integrin is critical for the trafficking of MCPs to the small intestine, they benefited from anti- $\alpha 4\beta 7$ integrin, anti- $\alpha 4$ integrin, anti- $\beta 7$ integrin, and anti-MAdCAM-1 mAbs to block the recovery of MCPs in the small intestine as late as 4 days after BM reconstitution. Applying the strategy of inhibition, they concluded that MCPs must arise first in the BM, circulate in the vascular system, and then translocate into the intestine [51]. A “mast cell/basophil-like” (MCBL) cell with cytoplasmic histamine and heparin content was reported in the hemolymph (a fluid equivalent to blood in invertebrate creatures) of *Styela plicata*, a solitary ascidian that abounds in shallow, protected environments in tropical and warm-temperate oceans best known for possessing a unique allorecognition system [52, 53], which appeared around 500 million years ago. Later, according to mouse model studies, it was suggested that both MCs and basophils originate from a granulocyte/monocyte progenitor (GMP) cell, which lineage specification is dependent to timed expression of the transcription factors GATA2 and C/EBP α . However, it has also been reported that MCs develop from common myeloid progenitors (CMPs), which are characterized by a lineage phenotype as (LIN)[–] KIT⁺ stem cell antigen 1 (SCA1) low FLT3[–] [54]. In the early 1990s, MCs were known to derive from BM CD34⁺/Fc ϵ RI[–] progenitors which transiently circulate in the bloodstream as morphologically

undifferentiated cells composed of a subset of circulating CD34⁺/CD117⁺/Ly[–]/CD14[–]/CD17[–] cells [55]. Most recently, Dahlin et al. reported a human Lin[–]/CD34hi/CD117int/hi/Fc ϵ RI⁺ CD13[–]/+integrin $\beta 7$ [–]/+ cell subset that gives rise to tryptase-positive granulated MCs expressing both CD117 and Fc ϵ RI at a frequency above 70% [56]. Chen et al. reported a cell population, identified as Lin[–] KIT⁺Sca-1[–] Ly6c[–] Fc ϵ RI α –CD27[–] $\beta 7$ + T1/ST2⁺, as MCPs in adult mouse BM [57]. Their results were consistent with results of Jamur et al. which benefited from applying AA4 and mAb BGD6 mAbs to purify the MCPs from mouse BM [49]. In a mouse model investigation based on studying the MCP and mature MCs from peritoneal lavage by flow cytometry, Dahlin et al. reported that once the committed MCPs leave the BM, they could be found in circulation as Lin[–] c-KIThi T1/ST2⁺ integrin b7hi CD16/32hi cells. After having entered the peripheral tissues, MCPs are identified with a CD45⁺ Lin[–] CD34⁺ integrin $\beta 7$ hi Fc ϵ RI α lo profile [47]. The experiment strongly suggests that MCPs are the progeny of multipotential progenitors (MPPs) other than common myeloid progenitors (CMPs) or granulocyte/macrophage progenitors. Furthermore, development of MCs from MPPs does not depend on cell division [58].

Further Mast Cell Surface Receptors and Mediators

A wide range of surface and cytoplasmic receptors make MCs capable of responding to various stimuli. Some of them are quite unusual and yet to be fully investigated. In this regard, the MC population is significantly higher in skin with direct exposure to light when compared with skin which is protected from sun exposure. Moreover ultra violet radiation may induce the MC activation. However, it is still not clear whether attraction of MCs to sun exposed skin or activation by ultra-violet follow a receptor signaling pathway and if so which receptor(s) is involved [59, 60]. Activation of MC expressed

chemokine receptors results in chemotaxis and induction of other stimulatory responses. For instance, the activation of CXCR3 and CCR2 promotes the migration of human cord blood MCs (hCBMCs) and induces the signaling events and partial degranulation even without the presence of antigens [61]. Histamine, which is the major mediator of MCs, delivers its biological effects through four receptors (H1–4). The H1 receptors (expressed by endothelial cells, bronchial, smooth muscle, and some neurons) and H2 receptors (expressed by vascular smooth muscle and gastric parietal cells) are associated with pathologic reactions including the wheal and flare reaction in skin, bronchoconstriction, drop in blood pressure, and gastrointestinal hyperactivity. H3 receptors are expressed primarily by the CNS, whereas H4 receptors are histamine receptors expressed on the surface of granulocytes including basophils, MCs, and eosinophils and participate in the process of chemotaxis [62]. The pattern of MCs trafficking depends on their ability to recognize appropriate chemotactic stimuli. Numerous chemoattractants are capable of inducing chemotaxis in MC models [63]. The main chemokine and their corresponding receptors are summarized in Fig. 2. MCs not only store ATP as an autocrine/paracrine factor in their secretory granules but also express P2X receptors, which sense extracellular ATP [64]. MCs may also express inhibitory G protein–coupled receptors including the β 2-adrenergic receptor (β 2AR), A2B receptor (the receptor for adenosine), and EP2 (PGE2 receptor) [65] Fig. 2. It should be considered that tissue resident MCs may differ in terms of expressing complement receptors. In this regard, unlike skin MCs, lung MCs do not express the C5a receptor (CD88) [66]. Some recently discovered MC receptors may have therapeutic importance, for instance, sialic acid-binding Ig-like lectins (Siglec) that preferentially bind to α 2,8-disialyl and branched α 2,6-sialyl carbohydrate structures [67]. Considering that Siglec-8 is expressed selectively on the surface of human eosinophils, MCs, and basophils, it may be a promising molecular target for immunomodulation of diseases [68]. Targeting Siglec-8 may be promising in the treatment of MC-related diseases, including allergic asthma, chronic rhinosinusitis, chronic urticaria, and mastocytosis [69]. Another clinically important receptor is the G protein–coupled MRGPRX2 receptor which is the human analogue of the mouse Mrgprb2. It may be involved in anaphylactoid non-IgE-mediated adverse drug reactions, e.g., to neuromuscular blocking agents used during anesthesia or chinolone antibiotics such as ciprofloxacin [17]. Most recently, MC expression of Mrgpr family has gained attention in dermatology. Meixiong et al., using Mrgprb2^{-/-} mice model, reported that Mrgprb2 deficiency attenuates itch in allergic contact dermatitis (ACD) and that the activation of the receptor is IgE/FcεRI independent and results in non-histaminergic itching. They concluded that targeting Mrgprb2 signaling pathway may have promising therapeutic application [70]. Moreover, Green et al.




Fig. 2 Main MC surface receptors for cytokines, complement, and chemokines. The complete ligands for chemokine receptors are listed

investigated the involvement of Mrgprb2 in the process of pain by studying Mrgprb2^{-/-} mice in two models of incision and injection of Complete Freund's Adjuvant (CFA) and found that Mrgprb2 deficiency could reduce the pain hypersensitivity. Interestingly, the P substance/Mrgprb2 receptor





Fig. 3 **a** Schematic representation of the signaling events during KIT activation by SCF in MCs; **b** FcεRI-stimulated assembly of macromolecular signaling complexes

interaction plays a role in recruitment of innate immune cells to the site of inflammation [71].

KIT and IgE Signaling

KIT (CD117) belongs to the tyrosine kinase activity superfamily [72, 73]. SCF (first introduced as steel factor and became to be known as KIT ligand later) is synthesized as a transmembrane protein from two alternatively spliced mRNAs which are enzymatically cleaved to soluble or membrane-bound forms [74]. Dimerization of KIT induces activation of the inherent catalytic activity associated with the split tyrosine kinase domain contained within the cytosolic COOH-terminal region [75]. SCF binding to KIT facilitates the formation of a homodimeric state of c-KIT through placing between the Ig-like domain 4/5 of a couple of adjacent monomeric KIT receptors. This leads to transphosphorylation in the regions “juxtamembrane,” “kinase insert,” “kinase domain,” and, finally, “COOH-terminal tail.” To trigger the signaling cascade, phosphorylated residues serve as docking sites for surrounding signaling molecules including Src kinases, PI3K, Shc, and phospholipase Cγ (PLCγ). The triggered signalings of GTP exchanger molecule SOS, PI3K, PLCγ, and JAK2 result in activation of Ras-Raf-Map kinase (MAPK) cascade that consequently leads to an increase of the Ca²⁺ concentration and activation of a number of transcription factors required for the biological function of MCs (Fig. 3a). MC activation in type I allergy is mainly triggered by FcεRI when crosslinking of FcεRI allergen-bound IgE occurs [76]. According to the FcεRI structure, the α chain serves as a binding site to IgE. The receptor in addition of α chain has a tetraspanning β chain and two γ chains linked by disulfide bonds. The β subunit effectively boosts the signals induced by IgE/allergen interactions. Additionally, two γ subunits have a role in initiation and conducting of FcεRI downstream signaling [77]. Upon antigen binding, the FcεRI forms dimers. This activation initiates cytoplasmic signaling by rendering “immunoreceptor tyrosine-based activation motifs” (ITAMs) phosphorylated in the cytoplasmic ends of the β and γ subunits by engaging the Src-family protein tyrosine kinase Lyn. Syk is bound to ITAMs in the γ units through which it adopts to a spatial conformation susceptible to become phosphorylated by Lyn. Syk promotes the phosphorylation of several targets including TRAPs, LAT, and NTAL. TRAPs after having become phosphorylated act as plasma membrane docking points for binding of cytoplasmic SH2 domain containing molecules mainly Grb2 and “phospholipase Cγ” (PLCγ). The latter molecule after anchoring and becoming activated

catalyzes the “phosphatidylinositol 4,5-bisphosphate” (PIP₂) hydrolysis to form “diacylglycerol” (DAG) and inositol 1,4,5, -triphosphate (IP₃) which are mainly known as the second messengers. IP₃ binds to its receptors on the “endoplasmic reticulum” (ER) that promotes Ca²⁺ efflux from the ER. IP₃ activates the IP₃-receptor on the ER to release Ca²⁺. The calcium sensor stromal interaction molecule 1 (STIM1) then interacts with the ORAI1 membrane protein opening the CRAC channels allowing the increase in intracellular calcium. The final result of calcium influx is increasing of the free cytoplasmic Ca²⁺ concentration, which is necessary to trigger further signaling events [78–80] (Fig. 3b).

Biogenesis and Degranulation of MC Granules

Following the production of proteins to be secreted into MC cytoplasmic granules, these products are directed to the secretory pathway of the “rough endoplasmic reticulum” (RER). During the passage through the Golgi apparatus, posttranslational modifications occur on the proteins and they reach the “trans-Golgi network” (TGN) [81]. In the following step, a regulated fusion of unit granules is initiated (also called small fusogenic granules) and these granules bud from the trans-Golgi region [82]. Their fusion results in formation of progranules in a defined region by the outermost cisternae of Golgi, RER, and results in mature granules in the cytoplasm. Having left the zone as immature granules (type III granules), the progranules mature via fusing with surrendering immature or mature granules. During “condensation” the volume of the granules is reduced, the contents of the granules become organized, and various sizes of mature granules are generated. Type III granules are capable of fusing with endosomes or lysosomes (type I granules) to form type II granules (secretory lysosomes) [82, 83]. The preformed “secretory granules” (SG) act as degradative and secretory compartments and due to their lysosomal properties contain lysosomal enzymes, present lysosomal membrane proteins, therefore, they possess a low acidic pH, and are regulated by synaptotagmins [84] (Fig. 4a). During exocytosis, SGs through a mechanism called compound exocytosis form channels by fusing with each other. The process can proceed either in a multivesicular or sequential pathway. Sequential exocytosis involves the initial fusion of vesicles with the plasma membrane. Next, the vesicles will fuse with the first vesicle. In contrast, multivesicular exocytosis involves vesicles fusing together prior to having interacted with the cell membrane [85]. Additionally, “piecemeal” degranulation is another mechanism of exocytosis through which MCs degranulate. This mechanism is characterized by gradual loss of contents of cytoplasmic granules without distinguishable granule fusion [85]. According to the strength of the degranulating signal, the potency and capacity of exocytosis can be significantly boosted by compound secretion, and




Fig. 4 **a** The classical model of secretory granule formation starts within endoplasmic reticulum and Golgi to form progranules. The fusion of progranules results in immature granules which then fuse and, finally, give rise to mature granules which are exocytosed using a molecular mechanism mediated by a variety of proteins including SNARE proteins. **b** Main mechanisms of exocytosis that are being used through MC degranulation are piecemeal and compound exocytosis

transport to the membrane [84](Fig. 4b). The appropriate fusion of vesicles to the membrane depends on the presence of specific set of highly conserved proteins called “Soluble N-ethylmaleimide-sensitive factor attachment protein receptors” (SNAREs) [85, 86]. Multiple SNARE proteins including VAMP 8, 7, 4, 3, and 2; SNAP23; and syntaxins 6, 4, and 3 are engaged during MC exocytosis [84]. For instance, VAMP-8 deletion results in inhibition of cathepsin D and serotonin release; however, the release of histamine or TNF- α is not influenced by VAMP-8 deletion [87]. Other complexes involved in exocytosis are Rab GTPases that regulate exocytosis; for instance, Rab27a, when accompanied with its effector molecule Munc13–4, increases Fc ϵ RI-induced capacity of MC degranulation [32]. Membrane, retrieve upon exocytosis, is a crucial step required for maintaining its integrity by a series of regulated endocytosis. Thus, endocytosis is considered as an essential step in avoiding complete exhaustion of the vesicle system and for maintaining normal MC morphology. Three forms of exocytosis-coupled forms of endocytosis are known in MC biology: slow endocytosis mediated by clathrin (invagination and internalization of the surface membrane coated with clathrin, and then removing of the clathrin), kiss-and-run endocytosis (a proposed mechanism through which vesicles do not fully collapse into the membrane but they recycle just after closure of a fusion pore), and bulk endocytosis [88].

Mast Cell Mediators

MC mediators are traditionally classified as pre-stored and de novo synthesized. The latter are arachidonic acid metabolites produced and released rapidly and cytokines produced and secreted less quickly. (Table 3) The class of mediators stored in granules includes important biologic mediators among them serotonin, histamine, heparin, TNF- α , and enzymes such as tryptase and chymase. De novo synthesized mediators are produced following MC stimulation such as lipid mediators including LTs, PAF, and PGs. Another class of MC cytoplasmic content being released includes cytokines, chemokines, and growth factors such as IL-10, IL-3, IL-8, IL-1, IL-4, IL-5, GM-CSF, TGF- β , VEGF, TNF- α , CCL2, CCL5, fibroblast growth factor (FGF), and platelet-derived growth factors (PDGF). Their release occurs over a period of hours rather than minutes, except for the preformed cytokines including TNF- α due to the possibility of storing and

further SGs homotypic fusion results in a rapid discharge of SGs located distally, which bypasses the need for their

Table 3 Mast cell mediators and their main features and function

Mediator	Main features and functions Pre-stored mediators
Bioactive monoamines	Histamine and serotonin are 1,4/1,3-diamines produced by amino-acid decarboxylases [89] Involved in vasodilation, angiogenesis, mitogenesis, pain [90] The key biogenic amine released upon engaging IgE-FcεRI signaling pathway in
Histamine	Human MC (3–8 pg/cell) Measuring the concentration of plasma histamine remains problematic due to its short half-life (10–30 min) [91]
Serotonin	Involved in vasoconstriction, pain [90] Unlike humans, it is found in high concentrations in rodent MCs Acting as neurotransmitter Possibly involved in MC-neuron interactions [92]
Dopamine	Not found in human MCs Acting as neurotransmitter Potential role in MC-mediated signaling to nerve endings [92]
MC-specific proteases	Appear as fully enzymatically active biological compounds both in the presence or absence of anionic GAGs [33] Have capacity to electrostatically binding with high affinity to heparin [33] Contribute to maintain the barrier function of intestinal, clearance of helminths, and may support blood pressure upon occurrence the anaphylaxis through generation of angiotensin II [93]
Chymases	Have chymotrypsin-like specificities and belong to the serine protease class [41] Generate mature forms of IL-33 by acting on full-length IL-33 _{1–270} to activate ILC2s and eosinophils in vivo [94]
Tryptases	Major protein component found in the stored SGs in human MCs [95] Catalyze β-protryptase to active β-tryptase2 [95] The main tryptases in humans include βI-, βII-, and βIII and the enzymatically inactive α-tryptase [92] Soluble β-tryptases stimulate nerves by activating PAR2 affect airway smooth muscle and fibroblasts by acting as mitogens Recruit neutrophils and eosinophils and degranulate MCs [96] Found as an activated form inside of MC granules [97] Promote fibroblast collagen synthesis [98] Have trypsin-like cleavage specificities and belong to the serine protease class [41] Have clinically diagnostic importance (as minor diagnostic criterion) in diagnosis of systemic mastocytosis when > 20 ng/ml [91]
Carboxypeptidase A3	Contributes to the generation/degradation of angiotensin II, degradation of apolipoprotein B, and metabolism of leukotrienes [99] Synthesized as a proenzyme with a 94-amino-acid activation peptide [99] Specificity for cleaving proteins/peptides from C-terminal end [41] Zinc-dependent metalloprotease [41] with exopeptidase activity [99] De novo synthesized mediators
LTC4	promoting migration eosinophil, bronchoconstriction, and vascular permeability [100]
PGD2	Promotes vasodilatation, permeability, migration of inflammatory cells, and production of cytokines [100] Involved in bronchoconstriction, pain [90] Acting as chemoattractant factor for human airway smooth muscle (HASM) by interacting with the CRTH2/DP2 receptor and may promote ASM migration toward the subepithelial BM [101]
PAF	Activation of platelets, induction of bronchoconstriction, bronchial hyperresponsiveness, and chemotaxis of MC, increases vascular permeability, and accumulation of inflammatory cells [102]
PGE2	Seems to have profound immunosuppressive abilities [100]
Cytokine and growth factors	Main features and functions
TSLP	Also secreted from DCs and basophils; activates Th2 cells, MC, DCs, eosinophils, and basophils [100]
IL-3	Provokes IL-4, IL-13, histamine, and LTC4 release from basophils [100]
IL-4	Increases collagen production, stimulates synthesis of the extracellular matrix proteins including types I and III collagen and fibronectin in fibroblast culture [103] IL-4 supports the surface expression of FcεRI on MCs and basophils [104] Stimulates class switch of B cells to IgE production together with IL-5 and IL-13
IL-31	Also secreted from Th2 cells; involved in the T cells, MC, and eosinophils interaction with epithelial cells to release chemokines and other cytokines [100]
L-33	IL-33 promotes IgE/Ag-, SCF, C5a-, monomeric IgE- and NGF-mediated cytokine production in HMC-1 cell line and human MCs [105]

Table 3 (continued)

Mediator	Main features and functions Pre-stored mediators
IL-5	Dominant MC released cytokine involved in survival, trafficking, migration, differentiation, maturation, development, and biological function of eosinophils [100]
Nerve growth factor	Released upon FCεRI-crosslinking Mediates the interactions between MCs and peripheral nerve endings [92]
Stem cell factor	Present in the cytoplasm Not released upon IgE receptor crosslinking
TNF-α	Preformed cytokine stored in granules [2] Membrane-bound form optimizes the migration of tissue DCs to the draining LNs Soluble form participates in DC recruitment to sites of inflammation [106] Induces DC migration; increases DC longevity [106]
TGF-β1	Profibrotic multifunctional growth factor Stimulates fibroblast proliferation and matrix formation [107]
TGF-β2	Involves in marked collagen deposition [107]
Proteoglycans	Main features and functions
Chondroitin sulfate	Cartilage synthesis, anti-inflammatory
Heparin	Involved in angiogenesis; nerve growth factor stabilization
Hyaluronic acid	Connective tissue, stabilize NGF [90]

releasing it from cytoplasmic granules [108, 109]. Secretory granules contain many secretory compounds, mainly heparin/chondroitin sulfate proteoglycans with negative charge [33]. Heparin side chains of serglycin, which possess negatively charges, are required for appropriate storage of MC-restricted proteases as they possess positive charges. Additionally, serglycin has a role in regulation of the enzymatic activities of proteases [110]. Trypsases, chymases, and CPA3 are considered as MC-specific proteases but MC granules also possess MC non-specific proteases mainly cathepsin G, MMP9, active caspase3, ADAMTS5, granzyme B, and renin [92]. Among the lipid mediators of MCs, eicosanoids that are synthesized from a common precursor molecule, namely arachidonic acid (AA), play a prominent role [111].

Mast Cell-Deficient Mouse Models for Investigating Mast Cell Biology In Vivo

The proto-oncogene c-KIT is mapped to the dominant “white spotting locus” (W) on mouse chromosome 5. When mutations occur at the “murine-dominant white spotting locus” (W), they may influence biologic functions of variety of cells including the hematopoiesis, proliferation, and migration of primordial germ cells and melanoblasts during the process of embryogenesis. Many independent semidominant mutations have been identified at the W locus. Occurrence of the different alleles is associated with various degree of severity and effect on the different cell lineages [112]. The severity of the phenotypic traits influenced by mutations is in an inverse correlation with the activity of tyrosine kinase receptor [113]. So far, mice with a specific lack of all populations of MCs have

not been described yet; instead, mice deficient for KIT have been widely used to analyze the functions of MCs in vivo [114]. According to previously published data, two types of MC-deficient mice have been most frequently used for such studies, namely WBB6F1-Kit^W/Kit^{W-v} and C57BL/6-Kit^{W-sh}/Kit^{W-sh} mice. The main specifications are listed in (Table 4). The fertility accounts as an advantage for the Kit^{W-sh}/Kit^{W-sh} mice when researchers wished to produce MC-deficient mice with multiple genetic abnormalities. Additionally, more complex and expensive breeding strategies are required when sterile Kit^W/Kit^{W-v} mice are included in investigations [115]. Differences in biological responses in such mice and wild-type (WT) mice could be due to the presence of any of abnormalities, and not necessarily associated with MC-related deficiencies [117]. In recent years, novel Kit-independent MC-deficient mouse models have been developed and started to be used by many research labs (Table 4). Such models clearly benefit from the lack of Kit-mediated off-target effects, which have to be overcome in the Kit-dependent models by selective MC reconstitution strategies. On the other hand, these mice challenge the investigation of MC biology since their response differ from Kit-dependent mice in various disease models. Nevertheless, these new models open the scene for better mechanistic studies to further explore MC biology in vivo [121, 122].

MC Involvement in Type I Hypersensitivity


MCs were primarily known as the main effector cells in type-I allergic reactions and diseases, e.g., allergic rhinoconjunctivitis, urticaria, and anaphylaxis [123, 124]. The first pathogenic

Table 4 Main differences between two common types of MC-deficient mice

	Mutant mice with MC deficiency related to c-kit abnormalities		Mutant mice with MC deficiency unrelated to c-kit abnormalities	
	WBB6F1-Kit ^W /Kit ^{W-v}	C57BL/6-Kit ^{W-sh} /Kit ^{W-sh}	Mcp15-Cre;R-DTA	Cpa3 ^{Cre/+} , Cre-Master
Genetic characterization/disorder	Kit ^{W-v} reduces the kinase activity of the receptor	Kit ^{W-sh} is an inversion mutation affecting the transcriptional regulatory elements upstream of the c-kit transcription start site on mouse chromosome 5 [114]	Crossed MC protease (Mcp)5-Cre transgenic mice with R-DTA ^{fl/n} mice	Crossed MC protease Cpa3-Cre transgenic mice with McI-1 floxed mice
Cell deficiency rather than MCs	Lack of melanocytes, germ cells, interstitial cells of Cajal [115]	Reduced melanocytes		Marked deficiency in basophils (58–78%)
Sterility	Sterile [116]	Fertile	Fertile	Fertile
Hematologic abnormalities	Macrocytic anemia have reduced numbers of neutrophils and basophils [117]	Increased numbers of neutrophils and basophils		Reduction in bone marrow, blood and spleen basophils. Exhibit markedly reduced MC-dependent tissue swelling and leukocyte recruitment in IgE-dependent PCA [26]
Coat color	White [116]	Heterozygotes are black with a broad white sash/belt in the lumbar region while homozygous W ^{sh} mutant mice are black-eyed whites with small black patches [118]	Black	Black
Other	Have < 1% the wild-type levels of skin MCs	Enlarged spleens and mild cardiomegaly [117] Reduced muscular fitness	Lack of MCs in peritoneal, abdominal, back skin, and ear skin [114]	Known as “Hello Kitty” mice, marked kit-independent constitutive reduction in numbers of MCs [114] Profound depletion of MCs, deleting 28 nucleotides of the first exon of Cpa3, that encodes for the MC-associated protease CPA3 [119] Refractory to IgE-mediated anaphylaxis [120]

DTA diphtheria toxin alpha chain, *Cre-Master* Cre-mediated mast cell eradication

Fig. 5 DCs act as APCs by allergen uptake and a migrating to regional lymph nodes, afterwards. This is mediated by ILC-2, which release IL-13 onto the activated, naïve lymphocyte, which favors the differentiation to Th2 cells. IgE class switching of B cells occurs in lymph nodes and allergen-specific IgE is produced. The IgE is released into the serum, loaded onto the FcεRI receptor, and the MC becomes sensitized. Further exposure to allergen results in rapid, IgE-dependent activation of MCs, degranulation, and release of different classes of mediators involved in orchestration of the cellular and molecular events during immediate and late phases



localization observed in RA occur in response to local release of several MC-derived mediators. Tryptase when complexing with heparin promotes the inflammatory responses. For instance, it induces the release of neutrophil chemotactic factors mainly IL-1 β , IL-17, IL-33, and TNF- α by synovial fibroblasts. IL-33, in turn, promotes the expression of additional inflammatory cytokines and chemokines through acting directly on MCs. Additionally, tryptase/PAR2 interaction activates synovial fibroblasts and enhances their capacity to produce proteases capable of degrading the structure of cartilage and bone [130]. MC-derived mediators including histamine, VEGF, LTs, and PGs have a role in increasing of vascular permeability and angiogenesis. Additionally, mediators such as heparin, MIP-1 α , TNF- α , IL-1, histamine, and RANKL are capable of inducing differentiation and activation of osteoclasts that is associated with bone destruction in RA [131, 132]. IL-6 and IFN- γ are able to activate macrophages [131]. (Fig. 6a).

Multiple Sclerosis

In MS, autoreactive T cells become activated in the periphery as aggressive effector cells that infiltrate the CNS. MCs interact with astrocytes (through CD40-CD40L interaction), neurons (through releasing proteases), and T cells for recruiting immune cells and damaging myelinated neurons. Peptidergic neurons modulate MC activity by secreting neuromediators: mainly substance P, which effectively induces histamine release from brain MCs [133]. Histamine released by MCs facilitates the penetration of autoreactive T cells into the CNS through CNS surrounding blood brain barrier (BBB) by alteration of vascular permeability [133]. MCs are capable to recruit inflammatory cells such as neutrophils by secreting TNF- α . Moreover, MC proteases have myelinolytic capacity; in return, some myelin proteins released from damaged myelin sheaths are potent to stimulate MC degranulation [133]. MC chemokines, among these mainly CCL2, CCL3, CCL4, CCL5, and IL-16, enhance T cell recruitment to the site of inflammation [134]. Additionally, MCs acting as APCs activate T cells through presentation of myelin antigens to T cells [135, 136]. In this regard, MCs express a large number of costimulatory molecules, including 4-1BB, CD40L, OX40L, CD80, CD86, and CD153, to activate T cells [137] (Fig. 6b).

Cancer and Tumor Progression

The complex role of MCs in shaping tumor microenvironment and interactions with a variety of tumor resident cells such as infiltrating immune cells, and tumor cells and, as well as the extracellular matrix have been investigated [138]. MCs can be recruited to the tumor microenvironment by tumor-derived SCF. In cancer biology, mediators released from MCs are described to be involved in angiogenesis, the growth and survival

of tumor cells, invasion, and metastasis [139]. In a tumor with MC-remodeled microenvironment, NF- κ B and AP-1 have intensified activity. Additionally, suppression of T cells and natural killer (NK) cells is exacerbated in such a microenvironment [140]. Among the cytokines contributing to tumor inflammation, TNF- α , IL-6, VEGF, iNOS, Cox-2, and MMP-9 can be produced by MCs [140]. Histamine may have a modulatory role in the chronic inflammatory responses associated with developing neoplasms through having interaction with its four G protein-coupled receptors. Histamine by acting via H1R regulates T cell polarization, in favor of enhancing Th1 responses. Additionally, while acting via H2R, histamine inhibits both Th1 and Th2 responses. Moreover, MC-released histamine plays a role in MC/peripheral monocytes interactions through acting on monocyte expressed H2R. Histamine also promotes IL-10 production and reduces the secretion of IL-12, and polarizes the skewness of engaged naive CD4⁺ T cells toward a Th2 phenotype [139]. Tryptase activates latent MMPs that is associated with the ECM degradation, vascular tube formation, and release of angiogenic compounds [141]. MCs-Treg cells crosstalk through the OX40/OX40 ligand (OX40L) axis to inhibit histamine release in anaphylactic reactions. In the presence of IL-6, MCs can revert Treg cell suppressive activity triggering OX40 on their membrane and promote Treg cells into pro-inflammatory cells which produce IL-17 [139]. It should be considered that Tregs may have a different profile of released cytokines in different models of cancers, thus may act in favor of suppressing the anti-tumor responses or support pro-inflammatory responses. For example, adenomatous polyp resident Tregs shift their production of IL-10 to IL-17 [142]. The interaction between MCs and MDSCs with CD14⁺ CD19⁺ HLA-DR⁻/low phenotype is thought to shape an immunosuppressive microenvironment at least in patients suffering from colon cancer and melanoma. MDSC-derived IL-17 actively recruits IL-9 producing Treg cells that provide IL-9 for the survival of tumor resident MCs [143]. The SCF produced by tumor cells not only acts as a survival factor for MCs but even promotes the production of MCs MMP-9 by these cells. MMP-9 is capable of clipping the membrane-bound SCF expressed by tumor cell that consequently promotes bioavailability of SCF. Tryptase when secreted from activated MCs enhances the activity of tumor cell COX through interacting with the PAR-2 receptors. In return, COX mediates the production of PGE-2 and activates MCs to secrete VEGF that induces the tumor angiogenesis [144] (Fig. 7a).

Wound Healing

MCs also participate in overlapping phases of wound healing including inflammation, proliferation, and remodeling [145]. Injury is capable of triggering MC activation after which release of preformed or de novo synthesized mediators occurs [145]. MC-derived histamine induces capillary permeability




Fig. 7 a Tumor cells facilitate the infiltration of MCs into tumor and contribute to their survival by releasing SCF. OX40-OX40L interaction between Tregs and MCs results in releasing suppressive cytokines by Tregs that suppress CD4 and CD8 T cell activities. MCs contribute to neo-angiogenesis via secreting mediators and they also play a role by releasing proteases and MMPs to modify the ECM. The interaction among tumor-infiltrating MCs, MDSCs, and Tregs results in formation of a highly immunosuppressive microenvironment and evade of tumor cells from immune response. **b** MCs participate in all stages of wound healing by releasing mediators involved in immune cell recruitment, activation, and proliferation of fibroblasts and their differentiation into myofibroblasts, collagen synthesis, and neo-angiogenesis

and vasodilation that promote neutrophil influx to the site. MC released vascular endothelial growth factor (VEGF), and IL-6 and IL-8 also have vasoactive bioactivity [146]. Tryptase binding to PAR2 on endothelial cells causes vasodilatation that facilitates the infiltration of neutrophils and other inflammatory mediators into the injury site [147]. During the proliferative stage, keratinocytes attract MCs toward the epidermis by releasing SCF. Histamine and tryptase stimulate dermal fibroblasts to release growth factors including FGF-2 or FGF-7, respectively [103]. MCs are able to promote the fibroblast proliferation via releasing VEGF, IL-4, and basic fibroblast growth factor (bFGF) [148, 149]. Owing to chemotactic and mitogenic effects of tryptase on fibroblasts, MCs interact actively with them and participate in fibroblast biological functions mainly synthesis of collagen, contraction, and terminally differentiation into myofibroblasts [81]. MC mediators including IL-8, IL-4, NGF, FGF-2, PDGF, TGF- β , and VEGF participate in neo-angiogenesis, fibrinogenesis, or re-epithelization, the biological functions and processes required to proceed and finalize the wound repair [150, 151] (Fig. 7b).

MCs Crosstalk with Immune Cells

Interaction with the Innate Immune System

MCs have crosstalk with myeloid-derived suppressor cells (MDSCs) and support not only their mobilization and infiltration into the tumor but also promote their ability to produce IL-17. MDSCs, in turn, attract Tregs and stimulate them to produce IL-9, a survival factor for MCs [152]. MC-released histamine induces MDSC activation, proliferation, and IL-4 and IL-13 production through acting on MDSC surface-expressed H1R and H2R receptors. This enhanced cytokine production results in the skewing of immune responses toward Th2 which supports occurrence of allergic events [153]. MCs and DCs gather around environmental interfaces and MC-derived soluble promote DC activation, migration to lymph nodes, and facilitate the process of Th2 polarization. Recently, Carroll-Portillo et al. reported a direct intercellular crosstalk through an immunological synapse between MCs and DCs. A formation of synapses promotes the exchange of MC internalized-

specific antigen and transfer it to surrounding DCs to be processed and presented to T cells for the purpose of their activation [154]. MC-derived IL-10 reduces DC migration, maturation, and activation while it enhances DCs ability of reducing T cell proliferation and cytokine production by downregulation of co-stimulatory molecule expression by DCs [98]. MCs released TNF- α and IL-1 promote DC migration and maturation; furthermore, cytokines including IL-18 and IL-16, CCL5, and PGE2 facilitate DC migration [155]. MC-derived TNF- α and IL-6 are involved in monocyte and macrophage activation and the local recruitment of neutrophils [156]. MC-derived IL-10 is potent to suppress the cytokine production by monocytes [98]. Upon LPS stimulation through TLR4/MyD88 signaling pathway, MCs and macrophages release CXCL1 and CXCL2 capable of binding to CXCR2 receptor through which they recruit neutrophils to the site [157]. MC-released MCP-6, tryptase β 2, and IL-5 are potent to recruit eosinophils [158]. A major role of MCs in innate immunity is to enhance the local recruitment of neutrophils by secreting TNF- α , which can either enhance host resistance or contribute to pathology [159]. Additionally, MC-derived mMCP-6 contributes to the recruitment of neutrophils to sites of bacterial infection [40]. MC interactions with ILCs include the production of PGD2 by MCs through which they promote the chemotaxis of ILC2s. Moreover, MCs upon becoming activated via IgE/Fc ϵ RI signaling or in response to extracellular ATP release IL-33 which induces the production of IL-13 by ILCs. The latter cytokine contributes to the restriction of helminth infection. MCs, after becoming activated by IL-9 from IL-33-elicited ILC2s, produce IL-2, which in return promotes the expansion of CD25⁺ ILC2 population [160] (Fig. 8).

Interaction with the Adaptive Immune System

MCs have surface expression of both MHC I and II molecules, and by having interaction with T cell-expressed TCRs, they induce antigen-specific clonal expansion of T cells [8]. Having direct interaction with CD4⁺ T cells via MHC II and OX40L and also releasing TNF- α , MCs augment their own activation, proliferation, and cytokine secretion (e.g., IL-22, IFN- γ) [8]. MCs promote the recruitment of CD8⁺ T cells by releasing CCL5 and LTB4 [8]. Tregs promote MCp recruitment to the lung during allergic inflammation, while Treg-derived IL-9 promotes recruitment of MCs into transplanted allografts, important for maintaining allograft tolerance [161]. Engagement of OX40L (expressed on MCs) and OX40 (expressed on Tregs) [152] is a mechanism through which Treg can suppress IgE-mediated MC degranulation [162]. Additionally, IL-10 and TGF- β secreted by Tregs have been shown to inhibit the Fc ϵ RI expression by MCs [163]. Moreover, MC-derived TGF- β contributes to generation of Tregs [106]. MCs augment IgE production of B cells by releasing IL-13 and IL-4 and expressing CD40L [98] (Fig. 8).

Mast Cells and Host Defense


Mast Cell Recognition of Microbial Infection

MCs express a broad range of cell surface receptors. These receptors are actively involved in the detection of harmful pathogenic microorganisms including viruses, parasites (mainly helminths), and bacteria. MCs respond to pathogens after detecting them by releasing mediators including TNF- α , LTs, and proteases as well as recruiting immune cells mainly neutrophils and DCs. MCs respond to microbial structures and products by recognizing PAMPs by the help of “pattern recognition receptors” (PRR). The main classes of PRRs are (1) “Toll-like receptors” (TLRs) which are expressed on plasma membrane or membrane of cytoplasmic endosomes and (2) the cytoplasmic “nucleotide-binding oligomerization domain” (NOD)-like receptor (NLRs) [62]. TLRs are defined as type-I transmembrane proteins possessing ectodomains containing leucine-rich repeats, which enable them to recognize the PAMPs and DAMPs. Over time, TLR1 to TLR9 conserved their structure in both mice and humans. However, in mice, TLR-10 is nonfunctional due to the presence of a retroviral insertion. TLR-11, TLR-12, and TLR-13 have not yet been determined in humans. TLR1, TLR-2, TLR-4, TLR-5, TLR-6, and TLR-10 are known to be widely expressed on the plasma membrane, while TLR3, TLR-7, TLR-8, TLR-9, TLR-11, TLR-12, and TLR-13 are expressed in the endosome [164]. TLRs are able to bind to diverse molecular structures, including lipids (TLR4: LPS via MD2; TLR2: lipoproteins), proteins (TLR5: flagellin; TLR2 and TLR4: HMGB1), and nucleic acids (TLR3: dsRNA; TLR7/8: ssRNA; and TLR9: unmethylated CpG motifs in bacterial, viral, and fungal DNA) [165]. Generally, the strength of signal generated by engaging TLRs is below the threshold needed for triggering calcium flux and granule exocytosis in MCs, except TLR2 [166]. TLR2 (through inducing the production of IL-6) and TLR4 signaling is significantly dominant in MC-mediated immune responses against bacteria. Interestingly, “lipopolysaccharide” (LPS)-TLR4 interaction has been shown to stimulate rodent MCs and promoting the cytokine production without occurrence of degranulation. In contrast to TLR-4, stimulation of MCs through TLR2 peptidoglycan interaction induces both degranulation and cytokine production [167]. MCs benefit largely from a wide range of proteins including immunoglobulins, complement components, and surfactant lipoproteins, which serve as opsonins to indirectly recognize and interact with bacteria [168].

Mast Cells and Defense Against Bacterial Infection

In addition to recognizing bacteria, MCs can recognize and respond to other dangers such as toxins. For instance, binding the *Vibrio cholerae* toxin-Ganglioside GM1 selectively

Fig. 8 MCs interact with cells of both the innate and adaptive immune system by releasing activating or suppressing mediators or engaging surface expressed receptors to have direct cell-to-cell interaction



promotes IL-6 production, while hampering the production of other mediators. Another example is *Clostridium difficile* toxin that induces MC degranulation after binding neurokinin-1 [168]. During bacterial infection, MCs are activated by engaging complement receptors (CRs), capable of being directly activated by bacterial products and expressed molecules including CD48 (bacterial expressed FimH receptor) [169]. Carlos et al. reported that MC activation results in acquiring resistance during infection with *Mycobacterium tuberculosis*. Their studied TLR2^{-/-} mice showed increased mycobacterial load, deficient recruitment of myeloid cells, and pro-inflammatory cytokine production. Adoptive transfer of TLR2^{+/+} MCs could effectively correct the susceptibility of TLR2-deficient mice to MTB infection [170]. MC-derived TNF- α is an effective neutrophil recruiting mediator to infection sites. Interestingly, MCs play an active role in antibacterial defense possessing bactericidal activity (e.g., by releasing cathelicidins or proteases). MC proteases have been reported to play a role in the control of gut infections. Mouse tryptase mMCP6 (but not the related protease mMCP7) attracts neutrophils when injected into the peritoneal cavity. Moreover, Mcpt6^{-/-} mice clear *Klebsiella pneumoniae* inefficiently and are more likely than +/+ mice to die following an injection of *K. pneumoniae* into the peritoneal cavity [93]. Following intranasal/intraperitoneal inoculation with *K. pneumoniae*, IL-6^{-/-} mice are less likely to survive than wild-type controls. At the time of death, IL-6^{-/-} mice were found to have higher bacterial load but not inflammatory cells in lungs and peritoneum [171]. Junkins et al. used MC-deficient Kit^{W-sh}/Kit^{W-sh} mice model to investigate the MCs capability in microbial defense against *Pseudomonas aeruginosa*. They found MC-deficient mice with greatly increased bacterial dissemination, epithelial permeability, and neutrophil load when compared with WT control group after *P. aeruginosa* infection. In their study, MCs were shown to reduce *P. aeruginosa*-mediated epithelial cell apoptosis and TNF production by epithelial cells [172]. Investigation of MCs involvement in skin immune defense in lesions induced by *P. aeruginosa* in MC-deficient Kit^W/Kit^{W-v} mice, normal Kit^{+/+} mice, and MC-reconstituted Kit^W/Kit^{W-v} mice suggested endothelin-1 as a possible mediator to induce activation of MCs to augment neutrophil recruitment to infection sites and therefore bacterial clearance [173].

Mast Cells and Defense Against Viral Infection and Toxins

In the context of viral infection, the TLR3-dependent activation of MCs by viruses hampers their capacity to attach to fibronectin and vitronectin. Additionally, TLR3 activation abrogates MC attachment-dependent potentiation of IgE-mediated responses. MCs produce type I IFNs in response to engaging endosomal TLR3 upon exposure to double-stranded

RNA [169]. Moreover, exposure to gp120 envelope protein of HIV promotes IL-4 and IL-13 production by MCs [169]. It has been proposed that MCs in HIV/AIDS act as inducible reservoirs of infectious viral clones. Gp120 is capable of activating MCs and basophils, via IgE binding to Fc ϵ RI. Consequently, a Th2-dominated response is generated that may downregulate the protective anti-viral immune responses [174]. MCs produce IFN in response to viral infection when stimulated through TLR3 and can modulate T cell responses to viral infections [175]. MC-derived TNF- α and IL-6 are able to protect mice from HSV-induced mortality. This has been reported after intradermal injection with HSV-2 into MC-deficient Kit^W/Kit^{W-v} mice [176]. Various microbes employ distinct mechanisms to suppress the role of MCs in host defense. For instance, the ES-62 protein, secreted by nematodes, is able to degrade PKC- α , an intermediate molecule in MC-activating cascade. *M. Toxoplasma* employs unknown factors to suppress MC degranulation by inhibition of signaling through tyrosine phosphorylation [177]. MCs may also play a protective role. In mouse models, MCs can protect from envenomation from bee [178] and scorpion stings, and snake bites [179]. For instance, MC-Carboxypeptidase 3 can degrade the snake venom toxin safarotoxin [109].

Conclusion

MCs, tissue-localized cells of hematopoietic origin, are best known for their harmful effects when eliciting immediate hypersensitivity reactions. However, in recent times, they have gained attention as major effector cells in numerous other pathological but also physiological situations. Owing to the expression of a variety of receptors and a wide spectrum of mediators, MCs play a role in many inflammatory diseases, tissue remodeling, and anti-tumor immune responses. Moreover, they continue to play a crucial role in anti-microbial defense and tissue repair mechanisms due to their anatomical distribution at sites that exhibit direct interaction with the surrounding environment. The current knowledge of MC biology is based on four techniques, namely (1) transgenic and mutant mice, (2) human and mouse MC lines, (3) MC targeting antibodies, and (4) pharmacological strategies to modulate MC activation or mediator effects. Current insights into the role of MCs in the pathophysiology of variety of MC-involved diseases are mostly gained through investigations on animal models and the extension of these roles to human diseases requires further cellular and molecular investigations. According to the complexity of immune responses orchestrated by MCs due to expression of variety of receptors some of which have recently determined, and the differences in degranulation profile of MCs subsets in response to different stimuli, it should be considered that implying the in vitro

laboratory results to clinically significant disorders needs further investigation to avoid any unwanted extrapolation.

Authors' Contributions Daniel Elieh Ali Komi, Stefan Wöhrle, and Leonard Bielory have been directly involved in the preparation of the manuscript. Daniel Elieh Ali Komi has designed and created the figures. Leonard Bielory and Stefan Wöhrle have reviewed, revised, and added inputs.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

Ethical Approval This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent No informed consent was required to prepare the manuscript.

References

- Crivellato E, Beltrami C, Mallardi F, Ribatti D (2003) Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. *Br J Haematol* 123(1):19–21
- Seneviratne SL, Maitland A (2017) Mast cell disorders in Ehlers-Danlos Syndrome 175(1):226–236. <https://doi.org/10.1002/ajmg.c.31555>
- Friberg U, Graf W, Aberg B (1951) On the histochemistry of the mast cells. *Acta Pathol Microbiol Scand* 29(2):197–202
- Leclerc M, Desnoyers M, Beauchamp G, Lavoie JP (2006) Comparison of four staining methods for detection of mast cells in equine bronchoalveolar lavage fluid. *J Vet Intern Med* 20(2):377–381
- Muller T (1994) Supravital uptake of cationic dyes by mast cell granules: a light and electron microscope study. *Biotech Histochem Off Publ Biol Stain Comm* 69(3):171–176
- Goldstein SM, Kaempfer CE, Kealey JT, Wintroub BU (1989) Human mast cell carboxypeptidase. Purification and characterization. *J Clin Invest* 83(5):1630–1636. <https://doi.org/10.1172/jci114061>
- Gibson S, Miller HR (1986) Mast cell subsets in the rat distinguished immunohistochemically by their content of serine proteinases. *Immunology* 58(1):101–104
- Bulfone-Paus S, Bahri R (2015) Mast cells as regulators of T cell responses. *Front Immunol* 6:394. <https://doi.org/10.3389/fimmu.2015.00394>
- Beaven MA (2009) Our perception of the mast cell from Paul Ehrlich to now. *Eur J Immunol* 39(1):11–25. <https://doi.org/10.1002/eji.200838899>
- Kinet JP (1999) The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. *Annu Rev Immunol* 17:931–972. <https://doi.org/10.1146/annurev.immunol.17.1.931>
- Frangji P, Tkaczyk C, Oskereitzián C, David B, Desaymard C, Mecheri S (1996) Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. *Eur J Immunol* 26(10):2517–2528. <https://doi.org/10.1002/eji.1830261036>
- Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. *EMBO J* 6(11):3341–3351
- Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS et al (1990) Identification of a ligand for the c-kit proto-oncogene. *Cell* 63(1):167–174
- Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. *Proc Natl Acad Sci U S A* 92(23):10560–10564
- Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ (2005) Mast cell-deficient W-sh/c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. *Am J Pathol* 167(3):835–848. [https://doi.org/10.1016/s0002-9440\(10\)62055-x](https://doi.org/10.1016/s0002-9440(10)62055-x)
- Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. *Nat Med* 2(5):561–566
- McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, Dong X (2015) Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature* 519(7542):237–241. <https://doi.org/10.1038/nature14022>
- Ginsburg H, Lagunoff D (1967) The in vitro differentiation of mast cells. Cultures of cells from immunized mouse lymph nodes and thoracic duct lymph on fibroblast monolayers. *J Cell Biol* 35(3):685–697
- Ishizaka K, Ishizaka T, Hornbrook MM (1966) Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity with gamma-E-globulin antibody. *J Immunol (Baltimore, Md : 1950)* 97(6):840–853
- Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD (1999) Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). *Blood* 94(7):2333–2342
- Young JD, Liu CC, Butler G, Cohn ZA, Galli SJ (1987) Identification, purification, and characterization of a mast cell-associated cytolytic factor related to tumor necrosis factor. *Proc Natl Acad Sci U S A* 84(24):9175–9179
- Nakano T, Sonoda T, Hayashi C, Yamatodani A, Kanayama Y, Yamamura T, Asai H, Yonezawa T, Kitamura Y, Galli SJ (1985) Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/W^v mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. *J Exp Med* 162(3):1025–1043
- Edwards AM (2005) The discovery of cromolyn sodium and its effect on research and practice in allergy and immunology. *J Allergy Clin Immunol* 115(4):885–888. <https://doi.org/10.1016/j.jaci.2005.01.063>
- Dudeck A, Dudeck J, Scholten J, Petzold A, Surianarayanan S, Kohler A, Peschke K, Vohringer D, Waskow C, Krieg T, Muller W, Waisman A, Hartmann K, Gunzer M, Roers A (2011) Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. *Immunity* 34(6):973–984. <https://doi.org/10.1016/j.immuni.2011.03.028>
- Otsuka A, Kubo M, Honda T, Egawa G, Nakajima S, Tanizaki H, Kim B, Matsuoka S, Watanabe T, Nakae S, Miyachi Y, Kabashima K (2011) Requirement of interaction between mast cells and skin dendritic cells to establish contact hypersensitivity. *PLoS One* 6(9):e25538. <https://doi.org/10.1371/journal.pone.0025538>
- Lilla JN, Chen CC, Mukai K, BenBarak MJ, Franco CB, Kalesnikoff J, Yu M, Tsai M, Piliponsky AM, Galli SJ (2011) Reduced mast cell and basophil numbers and function in Cpa3-Cre; mcl-1fl/fl mice. *Blood* 118(26):6930–6938. <https://doi.org/10.1182/blood-2011-03-343962>

27. Reber LL, Sibilano R, Mukai K, Galli SJ (2015) Potential effector and immunoregulatory functions of mast cells in mucosal immunity. *Mucosal Immunol* 8(3):444–463. <https://doi.org/10.1038/mi.2014.131>
28. Gri G, Frossi B, D'Inca F, Danelli L, Betto E, Mion F, Sibilano R, Pucillo C (2012) Mast cell: an emerging partner in immune interaction. *Front Immunol* 3:120. <https://doi.org/10.3389/fimmu.2012.00120>
29. Gilfillan AM, Austin SJ, Metcalfe DD (2011) Mast cell biology: introduction and overview. *Adv Exp Med Biol* 716:2–12. https://doi.org/10.1007/978-1-4419-9533-9_1
30. Nocka K, Buck J, Levi E, Besmer P (1990) Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. *EMBO J* 9(10):3287–3294
31. Campillo-Navarro M, Chavez-Blanco AD, Wong-Baeza I, Serafin-Lopez J, Flores-Mejia R, Estrada-Parra S, Estrada-Garcia I, Chacon-Salinas R (2014) Mast cells in lung homeostasis: beyond type I hypersensitivity. *Current Respiratory Medicine Reviews* 10(2):115–123. <https://doi.org/10.2174/1573398x10666141024220151>
32. Kalesnikoff J, Galli SJ (2008) New developments in mast cell biology. *Nat Immunol* 9(11):1215–1223. <https://doi.org/10.1038/ni.f.216>
33. Ronnberg E, Melo FR, Pejler G (2012) Mast cell proteoglycans. *J Histochem Cytochem Off J Histochem Soc* 60(12):950–962. <https://doi.org/10.1369/0022155412458927>
34. Vogel P, Janke L, Gravano DM, Lu M, Sawant DV, Bush D, Shuyu E, Vignali DAA, Pillai A, Rehgle JE (2018) Globule leukocytes and other mast cells in the mouse intestine. *Vet Pathol* 55(1):76–97. <https://doi.org/10.1177/0300985817705174>
35. Metcalfe DD, Baram D, Mekori YA (1997) Mast cells. *Physiol Rev* 77(4):1033–1079. <https://doi.org/10.1152/physrev.1997.77.4.1033>
36. Nakahata T, Kobayashi T, Ishiguro A, Tsuji K, Naganuma K, Ando O, Yagi Y, Tadokoro K, Akabane T (1986) Extensive proliferation of mature connective-tissue type mast cells in vitro. *Nature* 324(6092):65–67. <https://doi.org/10.1038/324065a0>
37. Tsuji K, Nakahata T, Takagi M, Kobayashi T, Ishiguro A, Kikuchi T, Naganuma K, Koike K, Miyajima A, Arai K et al (1990) Effects of interleukin-3 and interleukin-4 on the development of “connective tissue-type” mast cells: interleukin-3 supports their survival and interleukin-4 triggers and supports their proliferation synergistically with interleukin-3. *Blood* 75(2):421–427
38. Enerback L, Lundin PM (1974) Ultrastructure of mucosal mast cells in normal and compound 48-80-treated rats. *Cell Tissue Res* 150(1):95–105
39. Okabe T, Hide M, Hiragun T, Morita E, Koro O, Yamamoto S (2006) Bone marrow derived mast cell acquire responsiveness to substance P with ca(2+) signals and release of leukotriene B(4) via mitogen-activated protein kinase. *J Neuroimmunol* 181(1–2):1–12. <https://doi.org/10.1016/j.jneuroim.2006.07.011>
40. Galli SJ, Borregaard N, Wynn TA (2011) Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. *Nat Immunol* 12(11):1035–1044. <https://doi.org/10.1038/ni.2109>
41. Pejler G, Abrink M, Ringvall M, Wernersson S (2007) Mast cell proteases. *Adv Immunol* 95:167–255. [https://doi.org/10.1016/s0065-2776\(07\)95006-3](https://doi.org/10.1016/s0065-2776(07)95006-3)
42. Irani AM, Bradford TR, Kepley CL, Schechter NM, Schwartz LB (1989) Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. *J Histochem Cytochem Off J Histochem Soc* 37(10):1509–1515. <https://doi.org/10.1177/37.10.2674273>
43. Schwartz LB, Irani AM, Roller K, Castells MC, Schechter NM (1987) Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. *J Immunol* (Baltimore, Md : 1950) 138(8):2611–2615
44. Oliani SM, Vugman I, Jamur MC (1993) Ultrastructural similarity between bat and human mast cell secretory granules. *Int Arch Allergy Immunol* 100(3):230–233. <https://doi.org/10.1159/000236416>
45. Weidner N, Austen KF (1991) Ultrastructural and immunohistochemical characterization of normal mast cells at multiple body sites. *The Journal of Investigative Dermatology* 96(3):26S–30S discussion 30S–31S
46. Frossi B, Mion F, Sibilano R, Danelli L, Pucillo CEM (2018) Is it time for a new classification of mast cells? What do we know about mast cell heterogeneity? *Immunol Rev* 282(1):35–46. <https://doi.org/10.1111/imr.12636>
47. Dahlin JS, Ding Z, Hallgren J (2015) Distinguishing mast cell progenitors from mature mast cells in mice. *Stem Cells Dev* 24(14):1703–1711. <https://doi.org/10.1089/scd.2014.0553>
48. Guiraldelli MF, Franca CN, de Souza DA Jr, da Silva EZ, Toso VD, Carvalho CC, Jamur MC, Oliver C (2013) Rat embryonic mast cells originate in the AGM. *PLoS One* 8(3):e57862. <https://doi.org/10.1371/journal.pone.0057862>
49. Jamur MC, Moreno AN, Mello LF, Souza Junior DA, Campos MR, Pastor MV, Grodzki AC, Silva DC, Oliver C (2010) Mast cell repopulation of the peritoneal cavity: contribution of mast cell progenitors versus bone marrow derived committed mast cell precursors. *BMC Immunol* 11:32. <https://doi.org/10.1186/1471-2172-11-32>
50. Kitamura Y, Shimada M, Hatanaka K, Miyano Y (1977) Development of mast cells from grafted bone marrow cells in irradiated mice. *Nature* 268(5619):442–443
51. Gurish MF, Tao H, Abonia JP, Arya A, Friend DS, Parker CM, Austen KF (2001) Intestinal mast cell progenitors require CD49beta7 (alpha4beta7 integrin) for tissue-specific homing. *J Exp Med* 194(9):1243–1252
52. Oren M, Escande ML, Paz G, Fishelson Z, Rinkevich B (2008) Urochordate histoincompatible interactions activate vertebrate-like coagulation system components. *PLoS One* 3(9):e3123. <https://doi.org/10.1371/journal.pone.0003123>
53. Raftos DA, Tait NN, Briscoe DA (1987) Cellular basis of allograft rejection in the solitary urochordate, *Styela plicata*. *Dev Comp Immunol* 11(4):713–725
54. Voehringer D (2013) Protective and pathological roles of mast cells and basophils. *Nat Rev Immunol* 13(5):362–375. <https://doi.org/10.1038/nri3427>
55. Arock M (2016) Mast cell differentiation: still open questions? *Blood* 127(4):373–374. <https://doi.org/10.1182/blood-2015-12-686592>
56. Dahlin JS, Malinovsky A, Ohrvik H, Sandelin M (2016) Lin-CD34hi CD117int/hi FcepsilonRI+ cells in human blood constitute a rare population of mast cell progenitors. *Blood* 127(4):383–391. <https://doi.org/10.1182/blood-2015-06-650648>
57. Okayama Y, Kawakami T (2006) Development, migration, and survival of mast cells. *Immunol Res* 34(2):97–115. <https://doi.org/10.1385/ir.34:2:97>
58. Xu Y, Chen G (2015) Mast cell and autoimmune diseases. *Mediat Inflamm* 2015:246126. <https://doi.org/10.1155/2015/246126>
59. Grimbaldston MA, Simpson A, Finlay-Jones JJ, Hart PH (2003) The effect of ultraviolet radiation exposure on the prevalence of mast cells in human skin. *Br J Dermatol* 148(2):300–306. <https://doi.org/10.1046/j.1365-2133.2003.05113.x>
60. Kim MS, Kim YK, Lee DH, Seo JE, Cho KH, Eun HC, Chung JH (2009) Acute exposure of human skin to ultraviolet or infrared radiation or heat stimuli increases mast cell numbers and tryptase

- expression in human skin in vivo. *Br J Dermatol* 160(2):393–402. <https://doi.org/10.1111/j.1365-2133.2008.08838.x>
61. Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F (2012) Novel identified receptors on mast cells. *Front Immunol* 3: 238. <https://doi.org/10.3389/fimmu.2012.00238>
 62. Gilfillan AM, Beaven MA (2011) Regulation of mast cell responses in health and disease. *Crit Rev Immunol* 31(6):475–529
 63. Halova I, Draberova L, Draber P (2012) Mast cell chemotaxis - chemoattractants and signaling pathways. *Front Immunol* 3:119. <https://doi.org/10.3389/fimmu.2012.00119>
 64. Bulanova E, Bulfone-Paus S (2010) P2 receptor-mediated signaling in mast cell biology. *Purinergic Signal* 6(1):3–17. <https://doi.org/10.1007/s11302-009-9173-z>
 65. Stone KD, Prussin C, Metcalfe DD (2010) IgE, mast cells, basophils, and eosinophils. *J Allergy Clin Immunol* 125(2 Suppl 2): S73–S80. <https://doi.org/10.1016/j.jaci.2009.11.017>
 66. Kulka M, Metcalfe DD (2010) Isolation of tissue mast cells. *Current protocols in immunology Chapter 7:Unit 7.25*. <https://doi.org/10.1002/0471142735.im0725s90>
 67. Mizrahi S, Gibbs BF, Karra L, Ben-Zimra M, Levi-Schaffer F (2014) Siglec-7 is an inhibitory receptor on human mast cells and basophils. *J Allergy Clin Immunol* 134(1):230–233. <https://doi.org/10.1016/j.jaci.2014.03.031>
 68. O'Sullivan JA, Carroll DJ, Cao Y, Salicru AN, Bochner BS (2017) Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells. *J Allergy Clin Immunol*. <https://doi.org/10.1016/j.jaci.2017.06.028>
 69. Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS (2012) Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. *Pharmacol Ther* 135(3):327–336. <https://doi.org/10.1016/j.pharmthera.2012.06.005>
 70. Meixiong J, Anderson M, Limjunyawong N, Sabbagh MF, Hu E, Mack MR, Oetjen LK, Wang F, Kim BS, Dong X (2019) Activation of mast-cell-expressed mas-related G-protein-coupled receptors drives non-histaminergic itch. *Immunity* 50(5):1163–1171.e1165. <https://doi.org/10.1016/j.immuni.2019.03.013>
 71. Green DP, Limjunyawong N, Gour N, Pundir P, Dong X (2019) A mast-cell-specific receptor mediates neurogenic inflammation and pain. *Neuron* 101(3):412–420.e413. <https://doi.org/10.1016/j.neuron.2019.01.012>
 72. Frieri M, Patel R, Celestin J (2013) Mast cell activation syndrome: a review. *Curr Allergy Asthma Rep* 13(1):27–32. <https://doi.org/10.1007/s11882-012-0322-z>
 73. Blechman JM, Lev S, Givol D, Yarden Y (1993) Structure-function analyses of the kit receptor for the steel factor. *Stem Cells* (Dayton, Ohio) 11(Suppl 2):12–21. <https://doi.org/10.1002/stem.5530110804>
 74. Besmer P, Manova K, Duttlinger R, Huang EJ, Packer A, Gyssler C, Bachvarova RF (1993) The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. *Development* (Cambridge, Engl) Supplement:125–137
 75. Gilfillan AM, Rivera J (2009) The tyrosine kinase network regulating mast cell activation. *Immunol Rev* 228(1):149–169. <https://doi.org/10.1111/j.1600-065X.2008.00742.x>
 76. Alvarez-Errico D, Lessmann E, Rivera J (2009) Adapters in the organization of mast cell signaling. *Immunol Rev* 232(1):195–217. <https://doi.org/10.1111/j.1600-065X.2009.00834.x>
 77. Silveira ESAM, Mazucato VM, Jamur MC, Oliver C (2011) Lipid rafts in mast cell biology. *J Lipids* 2011:752906. <https://doi.org/10.1155/2011/752906>
 78. Blank U, Rivera J (2004) The ins and outs of IgE-dependent mast-cell exocytosis. *Trends Immunol* 25(5):266–273. <https://doi.org/10.1016/j.it.2004.03.005>
 79. Draber P, Sulimenko V, Draberova E (2012) Cytoskeleton in mast cell signaling. *Front Immunol* 3:130. <https://doi.org/10.3389/fimmu.2012.00130>
 80. Siraganian RP, de Castro RO, Barbu EA, Zhang J (2010) Mast cell signaling: the role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants. *FEBS Lett* 584(24):4933–4940. <https://doi.org/10.1016/j.febslet.2010.08.006>
 81. Blank U, Madera-Salcedo IK, Danelli L, Claver J, Tiwari N, Sanchez-Miranda E, Vazquez-Victorio G, Ramirez-Valadez KA, Macias-Silva M, Gonzalez-Espinosa C (2014) Vesicular trafficking and signaling for cytokine and chemokine secretion in mast cells. *Front Immunol* 5:453. <https://doi.org/10.3389/fimmu.2014.00453>
 82. Moon TC, Befus AD, Kulka M (2014) Mast cell mediators: their differential release and the secretory pathways involved. *Front Immunol* 5:569. <https://doi.org/10.3389/fimmu.2014.00569>
 83. Hammel I, Lagunoff D, Galli SJ (2010) Regulation of secretory granule size by the precise generation and fusion of unit granules. *J Cell Mol Med* 14(7):1904–1916. <https://doi.org/10.1111/j.1582-4934.2010.01071.x>
 84. Azouz NP, Hammel I, Sagi-Eisenberg R (2014) Characterization of mast cell secretory granules and their cell biology. *DNA Cell Biol* 33(10):647–651. <https://doi.org/10.1089/dna.2014.2543>
 85. Lorentz A, Baumann A, Vitte J, Blank U (2012) The SNARE machinery in mast cell secretion. *Front Immunol* 3:143. <https://doi.org/10.3389/fimmu.2012.00143>
 86. Woska JR Jr, Gillespie ME (2012) SNARE complex-mediated degranulation in mast cells. *J Cell Mol Med* 16(4):649–656. <https://doi.org/10.1111/j.1582-4934.2011.01443.x>
 87. Puri N, Roche PA (2008) Mast cells possess distinct secretory granule subsets whose exocytosis is regulated by different SNARE isoforms. *Proc Natl Acad Sci U S A* 105(7):2580–2585. <https://doi.org/10.1073/pnas.0707854105>
 88. Cabeza JM, Acosta J, Ales E (2013) Mechanisms of granule membrane recapture following exocytosis in intact mast cells. *J Biol Chem* 288(28):20293–20305. <https://doi.org/10.1074/jbc.M113.459065>
 89. Garcia-Faroldi G, Rodriguez CE, Urdiales JL, Perez-Pomares JM, Davila JC, Pejler G, Sanchez-Jimenez F, Fajardo I (2010) Polyamines are present in mast cell secretory granules and are important for granule homeostasis. *PLoS One* 5(11):e15071. <https://doi.org/10.1371/journal.pone.0015071>
 90. Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, Asadi S, Vasiadi M, Weng Z, Miniati A, Kalogeromitros D (2012) Mast cells and inflammation. *Biochim Biophys Acta* 1822(1):21–33. <https://doi.org/10.1016/j.bbadis.2010.12.014>
 91. Metcalfe DD, Pawankar R, Ackerman SJ, Akin C, Clayton F, Falcone FH, Gleich GJ, Irani AM, Johansson MW, Klion AD, Leiferman KM, Levi-Schaffer F, Nilsson G, Okayama Y, Prussin C, Schroeder JT, Schwartz LB, Simon HU, Walls AF, Triggiani M (2016) Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. *World Allergy Organ J* 9:7. <https://doi.org/10.1186/s40413-016-0094-3>
 92. Wernersson S, Pejler G (2014) Mast cell secretory granules: armed for battle. *Nat Rev Immunol* 14(7):478–494. <https://doi.org/10.1038/nri3690>
 93. Caughey GH (2011) Mast cell proteases as protective and inflammatory mediators. *Adv Exp Med Biol* 716:212–234. https://doi.org/10.1007/978-1-4419-9533-9_12
 94. Lefrancais E, Duval A, Mirey E, Roga S, Espinosa E, Cayrol C, Girard JP (2014) Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. *Proc Natl Acad Sci U S A* 111(43):15502–15507. <https://doi.org/10.1073/pnas.1410700111>
 95. Le QT, Gomez G, Zhao W, Hu J, Xia HZ, Fukuoka Y, Katunuma N, Schwartz LB (2011) Processing of human protryptase in mast cells involves cathepsins L, B, and C. *J Immunol* (Baltimore, Md :

- 1950) 187(4):1912–1918. <https://doi.org/10.4049/jimmunol.1001806>
96. Caughey GH (2007) Mast cell tryptases and chymases in inflammation and host defense. *Immunol Rev* 217:141–154. <https://doi.org/10.1111/j.1600-065X.2007.00509.x>
 97. Trivedi NN, Caughey GH (2010) Mast cell peptidases: chameleons of innate immunity and host defense. *Am J Respir Cell Mol Biol* 42(3):257–267. <https://doi.org/10.1165/rcmb.2009-0324RT>
 98. Galli SJ, Grimaldeston M, Tsai M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. *Nat Rev Immunol* 8(6):478–486. <https://doi.org/10.1038/nri2327>
 99. Henningsson F, Yamamoto K, Saftig P, Reinheckel T, Peters C, Knight SD, Pejler G (2005) A role for cathepsin E in the processing of mast-cell carboxypeptidase a. *J Cell Sci* 118(Pt 9):2035–2042. <https://doi.org/10.1242/jcs.02333>
 100. He SH, Zhang HY, Zeng XN, Chen D, Yang PC (2013) Mast cells and basophils are essential for allergies: mechanisms of allergic inflammation and a proposed procedure for diagnosis. *Acta Pharmacol Sin* 34(10):1270–1283. <https://doi.org/10.1038/aps.2013.88>
 101. Parameswaran K, Radford K, Fanat A, Stephen J, Bonnans C, Levy BD, Janssen LJ, Cox PG (2007) Modulation of human airway smooth muscle migration by lipid mediators and Th-2 cytokines. *Am J Respir Cell Mol Biol* 37(2):240–247. <https://doi.org/10.1165/rcmb.2006-0172OC>
 102. Kasperska-Zajac A, Brzozza Z, Rogala B (2008) Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. *Recent Patents Inflamm Allergy Drug Discov* 2(1):72–76
 103. Huttunen M, Aalto ML, Harvima RJ, Horsmanheimo M, Harvima IT (2000) Alterations in mast cells showing tryptase and chymase activity in epithelializing and chronic wounds. *Exp Dermatol* 9(4):258–265
 104. KleinJan A (2016) Airway inflammation in asthma: key players beyond the Th2 pathway. *Curr Opin Pulm Med* 22(1):46–52. <https://doi.org/10.1097/mcp.0000000000000224>
 105. Nakae S, Morita H, Ohno T, Arae K, Matsumoto K, Saito H (2013) Role of interleukin-33 in innate-type immune cells in allergy. *Allergol Int Off J Jpn Soc Allergol* 62(1):13–20. <https://doi.org/10.2332/allergolint.13-RAI-0538>
 106. de Vries VC, Noelle RJ (2010) Mast cell mediators in tolerance. *Curr Opin Immunol* 22(5):643–648. <https://doi.org/10.1016/j.coi.2010.08.015>
 107. Shiota N, Nishikori Y, Kakizoe E, Shimoura K, Niibayashi T, Shimbori C, Tanaka T, Okunishi H (2010) Pathophysiological role of skin mast cells in wound healing after scald injury: study with mast cell-deficient W/W(V) mice. *Int Arch Allergy Immunol* 151(1):80–88. <https://doi.org/10.1159/000232573>
 108. Wasiuk A, de Vries VC, Hartmann K, Roers A, Noelle RJ (2009) Mast cells as regulators of adaptive immunity to tumours. *Clin Exp Immunol* 155(2):140–146. <https://doi.org/10.1111/j.1365-2249.2008.03840.x>
 109. Overed-Sayer C, Rapley L, Mustelin T, Clarke DL (2013) Are mast cells instrumental for fibrotic diseases? *Front Pharmacol* 4:174. <https://doi.org/10.3389/fphar.2013.00174>
 110. Waern I, Karlsson I, Pejler G, Wernersson S (2016) IL-6 and IL-17A degradation by mast cells is mediated by a serglycin:serine protease axis. *Immun Inflamm Dis* 4(1):70–79. <https://doi.org/10.1002/iid3.95>
 111. Dichlberger A, Kovanen PT, Schneider WJ (2013) Mast cells: from lipid droplets to lipid mediators. *Clin Sci (Lond, Engl : 1979)* 125(3):121–130. <https://doi.org/10.1042/cs20120602>
 112. Nocka K, Majumder S, Chabot B, Ray P, Cervone M, Bernstein A, Besmer P (1989) Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice—evidence for an impaired c-kit kinase in mutant mice. *Genes Dev* 3(6):816–826
 113. Ronnstrand L (2004) Signal transduction via the stem cell factor receptor/c-kit. *Cell Mol Life Sci CMLS* 61(19–20):2535–2548. <https://doi.org/10.1007/s00018-004-4189-6>
 114. Reber LL, Marichal T, Galli SJ (2012) New models for analyzing mast cell functions in vivo. *Trends Immunol* 33(12):613–625. <https://doi.org/10.1016/j.it.2012.09.008>
 115. Galli SJ, Kalesnikoff J, Grimaldeston MA, Piliponsky AM, Williams CM, Tsai M (2005) Mast cells as “tunable” effector and immunoregulatory cells: recent advances. *Annu Rev Immunol* 23:749–786. <https://doi.org/10.1146/annurev.immunol.21.120601.141025>
 116. Wedemeyer J, Galli SJ (2005) Decreased susceptibility of mast cell-deficient kit(W)/kit(W-v) mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors. *Lab Invest J Tech Methods Pathol* 85(3):388–396. <https://doi.org/10.1038/labinvest.3700232>
 117. Galli SJ, Tsai M (2010) Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. *Eur J Immunol* 40(7):1843–1851. <https://doi.org/10.1002/eji.201040559>
 118. Duttlinger R, Manova K, Chu TY, Gyssler C, Zelenetz AD, Bachvarova RF, Besmer P (1993) W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. *Development (Cambridge, England)* 118(3):705–717
 119. Chmela J, Chatzigeorgiou A, Chung KJ, Prucnal M, Voehringer D, Roers A, Chavakis T (2016) No role for mast cells in obesity-related metabolic dysregulation. *Front Immunol* 7:524. <https://doi.org/10.3389/fimmu.2016.00524>
 120. Feyerabend TB, Weiser A, Tietz A, Stassen M, Harris N, Kopf M, Radermacher P, Moller P, Benoist C, Mathis D, Fehling HJ, Rodewald HR (2011) Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. *Immunity* 35(5):832–844. <https://doi.org/10.1016/j.immuni.2011.09.015>
 121. Feyerabend TB, Gutierrez DA, Rodewald HR (2016) Of mouse models of mast cell deficiency and metabolic syndrome. *Cell Metab* 24(1):1–2. <https://doi.org/10.1016/j.cmet.2016.06.019>
 122. Lei Y, Gregory JA, Nilsson GP, Adner M (2013) Insights into mast cell functions in asthma using mouse models. *Pulm Pharmacol Ther* 26(5):532–539. <https://doi.org/10.1016/j.pupt.2013.03.019>
 123. Elieh Ali Komi D, Rambasek T, Bielory L (2018) Clinical implications of mast cell involvement in allergic conjunctivitis. *Allergy* 73(3):528–539. <https://doi.org/10.1111/all.13334>
 124. Church MK, Kolkhir P, Metz M, Maurer M (2018) The role and relevance of mast cells in urticaria. *Immunol Rev* 282(1):232–247. <https://doi.org/10.1111/imr.12632>
 125. Lee CC, Lin CL, Leu SJ, Lee YL (2018) Overexpression of notch ligand Delta-like-1 by dendritic cells enhances their immunoregulatory capacity and exerts antiallergic effects on Th2-mediated allergic asthma in mice. *Clin Immunol (Orlando, FL)* 187:58–67. <https://doi.org/10.1016/j.clim.2017.10.005>
 126. Galli SJ, Tsai M (2012) IgE and mast cells in allergic disease. *Nat Med* 18(5):693–704. <https://doi.org/10.1038/nm.2755>
 127. Ciprandi G, Marseglia GL, Castagnoli R, Valsecchi C, Tagliacarne C, Caimmi S, Licari A (2015) From IgE to clinical trials of allergic rhinitis. *Expert Rev Clin Immunol* 11(12):1321–1333. <https://doi.org/10.1586/1744666x.2015.1086645>
 128. Shamji MH, Durham SR (2017) Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. *J Allergy Clin Immunol* 140(6):1485–1498. <https://doi.org/10.1016/j.jaci.2017.10.010>

129. Modena BD, Dazy K, White AA (2016) Emerging concepts: mast cell involvement in allergic diseases. *Transl Res J Lab Clin Med* 174:98–121. <https://doi.org/10.1016/j.trsl.2016.02.011>
130. Brown MA, Hatfield JK (2012) Mast cells are important modifiers of autoimmune disease: with so much evidence, why is there still controversy? *Front Immunol* 3:147. <https://doi.org/10.3389/fimmu.2012.00147>
131. Rivellese F, Nerviani A, Rossi FW, Marone G, Matucci-Cerinic M, de Paulis A, Pitzalis C (2017) Mast cells in rheumatoid arthritis: friends or foes? *Autoimmun Rev* 16(6):557–563. <https://doi.org/10.1016/j.autrev.2017.04.001>
132. Sato K, Takayanagi H (2006) Osteoclasts, rheumatoid arthritis, and osteoimmunology. *Curr Opin Rheumatol* 18(4):419–426. <https://doi.org/10.1097/01.bor.0000231912.24740.a5>
133. Elieh-Ali-Komi D, Cao Y (2016) Role of mast cells in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. *Clin Rev Allergy Immunol*. <https://doi.org/10.1007/s12016-016-8595-y>
134. Theoharides TC, Kempuraj D, Kourelis T, Manola A (2008) Human mast cells stimulate activated T cells: implications for multiple sclerosis. *Ann N Y Acad Sci* 1144:74–82. <https://doi.org/10.1196/annals.1418.029>
135. Conti P, Kempuraj D (2016) Important role of mast cells in multiple sclerosis. *Mult Scler Relat Disord* 5:77–80. <https://doi.org/10.1016/j.msard.2015.11.005>
136. Medic N, Vita F, Abbate R, Soranzo MR, Pacor S, Fabbretti E, Borelli V, Zabucchi G (2008) Mast cell activation by myelin through scavenger receptor. *J Neuroimmunol* 200(1–2):27–40. <https://doi.org/10.1016/j.jneuroim.2008.05.019>
137. Li H, Nourbakhsh B, Safavi F, Li K, Xu H, Cullimore M, Zhou F, Zhang G, Rostami A (2011) Kit (W-sh) mice develop earlier and more severe experimental autoimmune encephalomyelitis due to absence of immune suppression. *J Immunol (Baltimore, Md : 1950)* 187(1):274–282. <https://doi.org/10.4049/jimmunol.1003603>
138. Komi DEA, Redegeld FA (2019) Role of mast cells in shaping the tumor microenvironment. *Clin Rev Allergy Immunol*. <https://doi.org/10.1007/s12016-019-08753-w>
139. Rigoni A, Colombo MP, Pucillo C (2015) The role of mast cells in molding the tumor microenvironment. *Cancer Microenviron Off J Int Cancer Microenviron Soc* 8(3):167–176. <https://doi.org/10.1007/s12307-014-0152-8>
140. Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. *Blood* 112(4):1269–1279. <https://doi.org/10.1182/blood-2008-03-147033>
141. Maciel TT, Moura IC, Hermine O (2015) The role of mast cells in cancers. *F1000prime reports* 7:09. <https://doi.org/10.12703/p7-09>
142. Gounaris E, Blatner NR, Dennis K, Magnusson F, Gurish MF, Strom TB, Beckhove P, Gounari F, Khazaie K (2009) T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. *Cancer Res* 69(13):5490–5497. <https://doi.org/10.1158/0008-5472.Can-09-0304>
143. Danelli L, Frossi B, Pucillo CE (2015) Mast cell/MDSC a liaison immunosuppressive for tumor microenvironment. *Oncoimmunology* 4(4):e1001232. <https://doi.org/10.1080/2162402x.2014.1001232>
144. Ryan JJ, Morales JK, Falanga YT, Fernando JF, Macey MR (2009) Mast cell regulation of the immune response. *World Allergy Organ J* 2(10):224–232. <https://doi.org/10.1097/WOX.0b013e3181c2a95e>
145. Wulff BC, Wilgus TA (2013) Mast cell activity in the healing wound: more than meets the eye? *Exp Dermatol* 22(8):507–510. <https://doi.org/10.1111/exd.12169>
146. Kennelly R, Conneely JB, Bouchier-Hayes D, Winter DC (2011) Mast cells in tissue healing: from skin to the gastrointestinal tract. *Curr Pharm Des* 17(34):3772–3775
147. Ng MF (2010) The role of mast cells in wound healing. *Int Wound J* 7(1):55–61. <https://doi.org/10.1111/j.1742-481X.2009.00651.x>
148. Trautmann A, Toksoy A, Engelhardt E, Brocker EB, Gillitzer R (2000) Mast cell involvement in normal human skin wound healing: expression of monocyte chemoattractant protein-1 is correlated with recruitment of mast cells which synthesize interleukin-4 in vivo. *J Pathol* 190(1):100–106. [https://doi.org/10.1002/\(sici\)1096-9896\(200001\)190:1<100::aid-path496>3.0.co;2-q](https://doi.org/10.1002/(sici)1096-9896(200001)190:1<100::aid-path496>3.0.co;2-q)
149. Tellechea A, Leal EC, Kafanas A, Auster ME, Kuchibhotla S, Ostrovsky Y, Tecilazich F, Baltzis D, Zheng Y, Carvalho E, Zabolotny JM, Weng Z, Petra A, Patel A, Panagiotidou S, Pradhan-Nabzyk L, Theoharides TC, Veves A (2016) Mast cells regulate wound healing in diabetes. *Diabetes* 65(7):2006–2019. <https://doi.org/10.2337/db15-0340>
150. Artuc M, Hermes B, Steckelings UM, Grutzkau A, Henz BM (1999) Mast cells and their mediators in cutaneous wound healing—active participants or innocent bystanders? *Exp Dermatol* 8(1):1–16
151. Rao KN, Brown MA (2008) Mast cells: multifaceted immune cells with diverse roles in health and disease. *Ann N Y Acad Sci* 1143:83–104. <https://doi.org/10.1196/annals.1443.023>
152. Mekori YA, Herskho AY (2012) T cell-mediated modulation of mast cell function: heterotypic adhesion-induced stimulatory or inhibitory effects. *Front Immunol* 3:6. <https://doi.org/10.3389/fimmu.2012.00006>
153. Martin RK, Saleem SJ, Folgosa L, Zellner HB, Damle SR, Nguyen GK, Ryan JJ, Bear HD, Irani AM, Conrad DH (2014) Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. *J Leukoc Biol* 96(1):151–159. <https://doi.org/10.1189/jlb.5A1213-644R>
154. Carroll-Portillo A, Cannon JL, te Riet J, Holmes A, Kawakami Y, Kawakami T, Cambi A, Lidke DS (2015) Mast cells and dendritic cells form synapses that facilitate antigen transfer for T cell activation. *J Cell Biol* 210(5):851–864. <https://doi.org/10.1083/jcb.201412074>
155. Galli SJ, Nakae S, Tsai M (2005) Mast cells in the development of adaptive immune responses. *Nat Immunol* 6(2):135–142. <https://doi.org/10.1038/ni1158>
156. Dahdah A, Gautier G, Attout T, Fiore F, Lebourdais E, Msallam R, Daeron M, Monteiro RC, Benhamou M, Charles N, Davoust J, Blank U, Malissen B, Launay P (2014) Mast cells aggravate sepsis by inhibiting peritoneal macrophage phagocytosis. *J Clin Invest* 124(10):4577–4589. <https://doi.org/10.1172/jci75212>
157. De Filippo K, Dudeck A, Hasenberg M, Nye E, van Rooijen N, Hartmann K, Gunzer M, Roers A, Hogg N (2013) Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. *Blood* 121(24):4930–4937. <https://doi.org/10.1182/blood-2013-02-486217>
158. Hodges K, Kennedy L, Meng F, Alpini G, Francis H (2012) Mast cells, disease and gastrointestinal cancer: a comprehensive review of recent findings. *Transl Gastrointest Cancer* 1(2):138–150
159. Schramm R, Thorlacius H (2004) Neutrophil recruitment in mast cell-dependent inflammation: inhibitory mechanisms of glucocorticoids. *Inflamm Res Off J Eur Histamine Res Soc* 53(12):644–652. <https://doi.org/10.1007/s00011-004-1307-8>
160. Symowski C, Voehringer D (2017) Interactions between innate lymphoid cells and cells of the innate and adaptive immune system. *Front Immunol* 8:1422. <https://doi.org/10.3389/fimmu.2017.01422>
161. Ganeshan K, Bryce PJ (2012) Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF-beta. *J Immunol*

- (Baltimore, Md : 1950) 188(2):594–603. <https://doi.org/10.4049/jimmunol.1102389>
162. de Vries VC, Wasiuk A, Bennett KA, Benson MJ, Elgueta R, Waldschmidt TJ, Noelle RJ (2009) Mast cell degranulation breaks peripheral tolerance. *Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg* 9(10):2270–2280. <https://doi.org/10.1111/j.1600-6143.2009.02755.x>
 163. Hershko AY, Rivera J (2010) Mast cell and T cell communication; amplification and control of adaptive immunity. *Immunol Lett* 128(2):98–104. <https://doi.org/10.1016/j.imlet.2009.10.013>
 164. Satoh T, Akira S (2016) Toll-like receptor signaling and its inducible proteins. *Microbiol Spectr* 4(6). <https://doi.org/10.1128/microbiolspec.MCHD-0040-2016>
 165. Leifer CA, Medvedev AE (2016) Molecular mechanisms of regulation of toll-like receptor signaling. *J Leukoc Biol* 100(5):927–941. <https://doi.org/10.1189/jlb.2MR0316-117RR>
 166. St John AL, Abraham SN (2013) Innate immunity and its regulation by mast cells. *J Immunol (Baltimore, Md : 1950)* 190(9):4458–4463. <https://doi.org/10.4049/jimmunol.1203420>
 167. Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. *Nat Rev Immunol* 10(6):440–452. <https://doi.org/10.1038/nri2782>
 168. Chan CY, St John AL, Abraham SN (2012) Plasticity in mast cell responses during bacterial infections. *Curr Opin Microbiol* 15(1):78–84. <https://doi.org/10.1016/j.mib.2011.10.007>
 169. Saluja R, Metz M, Maurer M (2012) Role and relevance of mast cells in fungal infections. *Front Immunol* 3:146. <https://doi.org/10.3389/fimmu.2012.00146>
 170. Carlos D, Frantz FG, Souza-Junior DA, Jamur MC, Oliver C, Ramos SG, Quesniaux VF, Ryffel B, Silva CL, Bozza MT, Faccioli LH (2009) TLR2-dependent mast cell activation contributes to the control of mycobacterium tuberculosis infection. *Microbes Infect* 11(8–9):770–778. <https://doi.org/10.1016/j.micinf.2009.04.025>
 171. Sutherland RE, Olsen JS, McKinstry A, Villalta SA, Wolters PJ (2008) Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. *J Immunol (Baltimore, Md : 1950)* 181(8):5598–5605
 172. Junkins RD, Carrigan SO, Wu Z, Stadnyk AW, Cowley E, Issekutz T, Berman J, Lin TJ (2014) Mast cells protect against *Pseudomonas aeruginosa*-induced lung injury. *Am J Pathol* 184(8):2310–2321. <https://doi.org/10.1016/j.ajpath.2014.05.009>
 173. Siebenhaar F, Syska W, Weller K, Magerl M, Zuberbier T, Metz M, Maurer M (2007) Control of *Pseudomonas aeruginosa* skin infections in mice is mast cell-dependent. *Am J Pathol* 170(6):1910–1916. <https://doi.org/10.2353/ajpath.2007.060770>
 174. Walker ME, Hatfield JK, Brown MA (2012) New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action? *Biochim Biophys Acta* 1822(1):57–65. <https://doi.org/10.1016/j.bbadis.2011.02.009>
 175. Wang Z, Lai Y, Bernard JJ, Macleod DT, Cogen AL, Moss B, Di Nardo A (2012) Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides. *J Immunol (Baltimore, Md : 1950)* 188(1):345–357. <https://doi.org/10.4049/jimmunol.1101703>
 176. Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, Nakao A, Moriishi K, Nishiyama Y, Shimada S (2013) Mast cells play a key role in host defense against herpes simplex virus infection through TNF-alpha and IL-6 production. *J Invest Dermatol* 133(9):2170–2179. <https://doi.org/10.1038/jid.2013.150>
 177. Choi HW, Abraham SN (2015) Mast cell mediator responses and their suppression by pathogenic and commensal microorganisms. *Mol Immunol* 63(1):74–79. <https://doi.org/10.1016/j.molimm.2014.02.006>
 178. Elieh Ali Komi D, Shafaghat F, Zwiener RD (2017) Immunology of bee venom. *Clin Rev Allergy Immunol*. <https://doi.org/10.1007/s12016-017-8597-4>
 179. Galli SJ, Starkl P, Marichal T, Tsai M (2017) Mast cells and IgE can enhance survival during innate and acquired host responses to venoms. *Trans Am Clin Climatol Assoc* 128:193–221

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.